Open Angle or Secondary Glaucoma

Updated: July 11, 2024

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

pilocarpine

1 drop of 1%, 2%, or 4% solution 4 times a day

unoprostone ophthalmic

Administer one drop into each affected eye daily twice

metipranolol ophthalmic

One drop in affected eye(s) every 2 times a day

betaxolol ophthalmic

1 drop of suspension in each affected eye twice daily
1-2 drops of solution in each affected eye twice daily
If the dose regimen doesn’t help in reducing the intraocular pressure, utilize concomitant therapy with other miotics and pilocarpine, carbonic anhydrase inhibitors, and epinephrine

bimatoprost ophthalmic implant

Administer dose of 10 mcg implant through intracameral administration

travoprost intraocular implant (Pending FDA approval)

Awaiting FDA clearance to lower patients' excessive intraocular pressure (IOP) in those suffering with ocular hypertension or open-angle glaucoma

Dose Adjustments

N/A

travoprost/timolol

Indicated for open angle glaucoma
Administer one drop to the affected eye one time daily

levobunolol

1-2 drops in the affected eyes every 12 hours

betaxolol ophthalmic

1 drop of suspension in each affected eye twice daily
If the dose regimen doesn’t help in reducing the intraocular pressure, utilize concomitant therapy with other miotics and pilocarpine, carbonic anhydrase inhibitors, and epinephrine
Safety and efficacy of ophthalmic solution are not seen in patients with less than 18 years

Future Trends